Physician profile
Rachel Rivera
NPI 1437359346
$10,039.34
in general payments reported to CMS, 2019-2025
25 companies · $1,548 in 2025
The $1,548 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,838 · 2020: $1,017 · 2021: $1,374 · 2022: $1,597 · 2023: $1,461 · 2024: $1,204 · 2025: $1,548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,202 · Education: $10.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,202.41 |
| Education | $10.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $4,033.22 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Janssen Biotech, INC. | $1,494.34 | 2019-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $1,420.00 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Gilead Sciences, INC. | $1,316.90 | 2019-2025 | Biktarvy, Sunlenca |
| Janssen Products, LP | $382.97 | 2020-2022 | |
| Theratechnologies INC. | $160.89 | 2019-2025 | Egrifta, Trogarzo |
| Pfizer INC. | $153.92 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $131.05 | 2024-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $121.56 | 2022-2024 | Spravato |
| Genentech USA, INC. | $116.90 | 2021 | |
| Emd Serono, INC. | $112.15 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $101.79 | 2022-2025 | Rexulti, Abilify Asimtufii |
| Napo Pharmaceuticals INC | $91.92 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $78.02 | 2024-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Novo Nordisk INC | $64.13 | 2023-2024 | Rybelsus, Ozempic |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $43.20 | 2020-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.48 | 2025 | |
| Neurocrine Biosciences, INC. | $34.09 | 2025 | |
| Glaxosmithkline, LLC. | $31.74 | 2023-2025 | Arexvy, Shingrix, Pediarix |
| Seqirus USA INC | $26.40 | 2025 | Flucelvax, Fluad |
| Hologic Sales and Service, LLC | $20.05 | 2025 | Aptima, Thinprep 2000 Processor |
| Romark Laboratories, Lc | $17.71 | 2019 | |
| Cranial Technologies, INC | $16.11 | 2025 | Doc Band |
| Janssen Scientific Affairs, LLC | $15.00 | 2019 | |
| Alkermes, INC. | $13.80 | 2023 | Aristada, Lybalvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.